CD24 and Mutant p53: Emerging Therapeutic Targets in Prostate Cancer Progression
CD24 and mutant p53 represent promising therapeutic targets in metastatic castration-resistant prostate cancer (mCRPC). Translating these targeting strategies into clinical practice may help overcome current therapeutic challenges and improve patient outcomes.
Authors
- Yong Wang (ORCID: https://orcid.org/0000-0001-8724-0370)
- Gan Zhihao
- Xie Ruishi
- Lan Xintian
- Guo Lian yi
- Zhu Ming
- Han Tiezheng
- Yin Qinzhamusu
Institutions
- People 's Hospital of Jilin Province (CN)
- Changchun University of Chinese Medicine (CN)
Publication Details
- Journal
- Anti-Cancer Agents in Medicinal Chemistry
- Published
- 2026-01-05
- DOI
- https://doi.org/10.2174/0118715206405420251117053720
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00